ARSB and mucopolysaccharidosis type 6: Crucially, ARSB (Naglazyme, Biomarin) is clinically approved for the treatment of mucopolysaccharidosis VI, a lysosomal storage disorder (Muñoz-Rojas et al., 2010; Harmatz et al., 2004; Harmatz et al., 2005); thus, its inclusion in future human therapeutic treatments is plausible.